TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04794556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tight-fitting of KF94 mask with clip
Description: The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tight-fitting of KF94 mask with clip
Description: The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tight-fitting of KF94 mask with clip
Description: The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
Study: NCT05928676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vascanox® HP
Description: Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
Study: NCT05652413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted-Engage-PA
Description: Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
Study: NCT06248697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1/CTLA4-MSLN-CAR T cells
Description: BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
Study: NCT04965506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously (SC) once a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Dulaglutide administered subcutaneously (SC) once a week.
Study: NCT05388019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)
Description: Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)
Description: Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Self-Assessment
Description: Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
Study: NCT05737407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LUS-guided choice of Peep
Description: Choice of Peep guided by lung ultrasound to avoid atelectasis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard choice of Peep
Description: Choice of Peep according to standard practice
Study: NCT04849819

Intervention type: DRUG
Intervention: Corticosteroids, immunosuppressors, biological agents
Description: We do not prescribe new medications to patients but only observe their adverse effects on the eye.

Intervention type: DRUG
Intervention: Corticosteroids, immunosuppressors, biological agents
Description: We do not prescribe new medications to patients but only observe their adverse effects on the eye.
Study: NCT06048367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNSI-Fe(II) 30 mg
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNSI-Fe(II) 60 mg
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNSI-Fe(II) 90 mg
Description: The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
Study: NCT05996380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3167
Description: SHR-3167, Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-3167 Placebo
Description: SHR-3167 Placebo Single administration
Study: NCT06311110

Intervention type: OTHER
Intervention: Vancouver symptom score for dysfunctional elimination symptoms Questionnaire
Description: Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.

Intervention type: OTHER
Intervention: Vancouver symptom score for dysfunctional elimination symptoms Questionnaire
Description: Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.

Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire
Description: Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.

Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire
Description: Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.

Intervention type: OTHER
Intervention: Questionnaire concerning impaired toilettraining and comorbities
Description: Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.

Intervention type: OTHER
Intervention: Questionnaire concerning impaired toilettraining and comorbities
Description: Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
Study: NCT05843799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB-202
Description: Single i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single i.v. infusion
Study: NCT06074484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: 4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
Study: NCT05545943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-days of zero calorie restriction and whole-body cold-water immersion
Description: The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-days of calorie restriction
Description: The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
Study: NCT06141161

Intervention type: DRUG
Intervention: corticosteroids
Description: inhailed or oral corticosteroids

Intervention type: DRUG
Intervention: corticosteroids
Description: inhailed or oral corticosteroids
Study: NCT05545943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-days of zero calorie restriction without whole-body cold-water immersion
Description: 2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-days of usual diet with whole-body cold-water immersion
Description: Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
Study: NCT05358743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
Study: NCT04601116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 Mg Oral Tablet
Description: Atorvastatin 80 mg per day for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo 1 tablet per day for 2 years
Study: NCT05147025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revascularization
Description: Regain pulp vascularity for young permenant teeth
Study: NCT05469828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Standard of care
Study: NCT06127654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy lung sparing treatment plan
Description: CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
Study: NCT04783285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual cognitive stimulation therapy (iCST)
Description: The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
Study: NCT06431178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
Study: NCT05479266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
Study: NCT05228821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor Oral Tablet
Description: During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
Study: NCT04691180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study: NCT05355766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator, oral tablets
Study: NCT06504797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic massage
Description: automatic massage
Study: NCT03678350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Dosimetry for Intranoperative Therapy
Description: Undergo IO-PDT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo IO-PDT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV
Study: NCT05443971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo grid therapy
Study: NCT05754307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access Flap
Description: Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed Surgical Technique
Description: Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required.
Study: NCT04787393

Intervention type: DEVICE
Intervention: Heartfelt device
Description: The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.

Intervention type: DEVICE
Intervention: Connected weighing scales
Description: The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights.
Study: NCT06417138

Intervention type: OTHER
Intervention: biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)
Description: This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
Study: NCT04738682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital dietary registration
Description: The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital dietary registration
Description: The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dietary registration
Description: The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dietary registration
Description: The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
Study: NCT04993300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (TMS)
Description: The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
Study: NCT04875611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).